Centessa Pharmaceuticals plc (CNTA) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-27

Key Insights

The reporting person, Karen M. Anderson, exercised stock options for 41,076 ordinary shares and then sold the same amount of shares, indicating insider selling activity.
The sale of shares was executed pursuant to a pre-planned 10b5-1 trading plan, suggesting the transactions were part of a structured strategy rather than a one-off event.
The sale price of $30.1242 per share represents a significant premium over the $8.01 exercise price of the stock options, indicating the reporting person was able to realize substantial gains from the transaction.

Want the newest filings?

This analysis covers the filing from 2026-03-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-18

The Chief People Officer, Karen M. Anderson, exercised and sold a significant number of Centessa Pharmaceuticals stock options on March 16 and 17, 2026, suggesting potential insider selling activity.
The sales were executed pursuant to a pre-arranged 10b5-1 trading plan, indicating the transactions were part of a planned strategy rather than opportunistic.
The sale prices suggest the shares were sold at a premium to the exercise price, potentially generating substantial gains for the insider.

Other reports for Centessa Pharmaceuticals plc

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.